Xcout Intel
RyboDyn
RyboDyn is a biotechnology company that uses its proprietary RyboCypher platform, combining RNA sequencing and AI, to decode the dark proteome and identify hidden cancer targets. The company develops next-generation, antibody-based immunotherapies designed to address critical unmet needs in cancer treatment.
Subscribe to see RyboDyn’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
RyboDyn at a glance
RyboDyn is a drug discovery company. It has raised at least $14M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $10M in March 2026. Xcout tracks 9 named people at RyboDyn, including IMAD AJJAWI (Co-Founder & Chief Executive Officer).
RyboDyn leadership
- IMAD AJJAWICo-Founder & Chief Executive Officer
- COREY DAMBACHERFounder, President, & Chief Technology Officer
- KERRY WILSONCo-Founder & VP, Platform Development
- ASHLEY WOODFINCo-Founder & Bioinformatics Lead - Target Discovery
- ANDY BASSVP, Corporate Strategy
- ARIEL SCHWARTZVP, AI
3 more named people on record for RyboDyn, with roles, board committees and tenure — see the full roster →
RyboDyn funding rounds
At least $14M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $10M | 2 named | |
| Seed | $4M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
RyboDyn competitors
A few of RyboDyn's closest competitors — see the full list of competitors and alternatives →
Cassidy Bio is an AI-first biotechnology company founded in 2024 and based in Israel that is developing a programmable platform for gene editing. The company utilizes a genomic foundation model powered by artificial intelligence to design safer and more scalable gene editing therapies across various guides, editors, and delivery contexts.
Cellyrix Therapeutics is an Israeli biotechnology company that develops targeted cancer therapies by leveraging single-cell RNA sequencing and artificial intelligence. The firm operates as an oncology-focused drug discovery venture headquartered in Rehovot, Israel.
Coding Bio is an Oxford-based biotechnology company that combines a high-throughput wet lab and machine learning platform to screen, build, and deliver fully-assembled modular therapies like CARs and BiTEs.
Renasis Bio Ltd. is a stealth-mode private company headquartered in Rehovot, Israel, established in 2025. The firm is developing an AI-driven drug discovery platform focused on RNA-targeting small molecules to advance RNA druggability.
Orbital Therapeutics is a biotechnology company developing RNA medicines, with a focus on engineered circular RNA and delivery technologies. Its programs are intended to address diseases that may benefit from durable, programmable protein expression, serving patients and healthcare providers through potential therapeutic products.
Get RyboDyn's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on RyboDyn in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access